Institut Pasteur de Dakar To Manufacture Affordable Measles And Rubella Vaccine

  • Technology transfer of the MR vaccine is supported by the Bill & Melinda Gates Foundation in collaboration with Batavia Biosciences and the Univercells Group

Institut Pasteur de Dakar (IPD) has today announced the launch of a new program to
advance the development of a measles and rubella vaccine for manufacture in Senegal. The grant by the Bill & Melinda Gates Foundation will deploy Batavia’s Hip-Vax
intensified production process for GMP measles and rubella material and Univercells’ NevoLine™ technology platform to accelerate manufacturing and affordable access to essential and epidemic vaccines in Africa. IPD will produce the vaccine for essential, routine immunization campaigns in low- and middle-income countries and for
outbreak and catch-up campaigns.

Production will be transferred to the state-of-the-art MADIBA facility, a regional
manufacturing hub for COVID-19 and other epidemic vaccines with a capacity to
produce 300 million doses for use in Africa.

Dr Amadou Alpha Sall, CEO of IPD, said: “By manufacturing affordable measles and
rubella vaccines and diagnostics in Africa, the region will be one step closer to a
diversified manufacturing landscape for epidemic preparedness and improving the
supply chain for essential vaccines for routine immunization. This will help countries in the region build autonomy and reach every child with lifesaving vaccines.”

Dr Christopher Yallop, COO of Batavia Biosciences added: “We are privileged to be able to work with Institut Pasteur de Dakar and the Bill & Melinda Gates Foundation to
advance this innovative vaccine technology with a key manufacturing partner. Our
HIP-Vax manufacturing process technology, developed on the NevoLine™ platform, is
designed to deliver vaccines at high yield and very low cost, increasing affordability
and availability.”

José Castillo, co-founder of Univercells, commented: “We are honoured to partner
with Institut Pasteur de Dakar and Batavia Biosciences, and to participate in this
historic initiative that will increase access to the measles and rubella vaccines on the
African continent and across the globe. Supporting and nurturing biomanufacturing
autonomy is at the heart of Univercells’ mission, and we are thrilled that our
technology will help enable progress towards regional autonomy. Knowing that our breakthrough vaccine manufacturing platform NevoLine™, initially funded by the Bill & Melinda Gates Foundation in 2016, will now help accelerate the manufacture of
vaccines in Africa, is very exciting.”

Leave a Reply

Your email address will not be published. Required fields are marked *